• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

News

Article

The Weekly Roundup: August 4-8

Key Takeaways

  • Amlitelimab enhances clinical outcomes and quality of life in atopic dermatitis, offering potential for long-term disease control.
  • EVERESSE monopolar RF technology is praised for safety, comfort, and effective skin rejuvenation.
SHOW MORE

In case you missed it, this week we had news about a novel PDE4 inhibitor for plaque psoriasis, the evolution of 5-ALA, a new melanoma treatment plan combining vidutolimod with pembrolizumab, and more.

dermatology times weekly roundup graphic

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Amlitelimab Improves QoL and Disease Control in AD

Amlitelimab shows promise in enhancing clinical outcomes and patient quality of life in atopic dermatitis, offering potential for long-term disease control.

How EVERESSE Monopolar RF is Revolutionizing Patient Care, According to Dendy Engelman, MD, FACMS, FAAD

Dendy Engelman, MD, FACMS, FAAD, explores the benefits of EVERESSE monopolar RF technology, emphasizing safety, comfort, and effective skin rejuvenation.

Molecular Insights Into ICI-Induced Skin Toxicities

Cutaneous immune-related adverse events (cirAEs) from immune checkpoint inhibitors (ICIs) show distinct immune profiles from classic skin conditions.

Vidutolimod Combo Therapy Shows Promise in Treating Advanced Melanoma

New clinical trial results reveal that intratumoral vidutolimod combined with pembrolizumab shows promise for treating advanced melanoma resistant to PD-1 therapy.

Real Cases Drive Honest Dialogue on Topicals for AD

Temitayo Ogunleye, MD, guided clinicians through diverse AD cases to examine how newer agents fit into evolving treatment strategies.

Immutep Gains FDA Support for Eftilagimod Alfa Development in HNSCC Patients with Low PD-L1 Expression

Immutep advances eftilagimod alfa for head and neck squamous cell carcinoma, targeting patients with low PD-L1 expression and limited treatment options.

Inadequate Relief for Patients with CSU Is Driving a Search for Alternatives Around the World

According to a new poster, patients with chronic spontaneous urticaria seek better relief options, highlighting significant impacts on quality of life and mental well-being globally.

Sybert Stresses Smart Genetic Testing in Dermatology

Virginia Sybert, MD, emphasized the importance of using genetic testing judiciously in dermatologic care.

Elevate-Derm Summer 2025: Full Conference Recap

Unlock exclusive insights from Elevate-Derm Summer 2025 and get expert pearls, emerging data, and clinical strategies at your fingertips.

Journal Digest: August 6, 2025

This review of the latest dermatologic studies includes a review of photoprotection in patients with skin of color, the presence of inflammatory cytokines in acne patients after isotretinoin treatment, perceptions of skin-lightening products in medical students, and more.

Are Schools Failing Children with Chronic Health Conditions?

Parents advocate for children with chronic skin conditions, highlighting school challenges and the need for better support in pediatric dermatology.

Q&A: Rolf-Markus Szeimies, MD, on the Evolution of 5-ALA

Discover how Rolf-Markus Szeimies, MD, is revolutionizing at-home skin care with 5-ALA, enhancing cellular health and hydration in daily routines.

Call for Best Practices in Medication Sampling

Explore the complexities of medication sampling, balancing patient access with ethical and safety concerns in clinical practice.

Split-Face Study Reveals New Role for BoNT-A

Patients receiving BoNT-A plus topical cream reported greater satisfaction and better skin lightness than with cream alone.

Time Equals Follicles: The Evolving Landscape of Hair Loss Treatment with Alan J. Bauman, MD

In this exclusive Q&A, Alan J. Bauman, MD, shares expert insights on innovative hair loss treatments, early intervention strategies, and the future of alopecia care.

50th Annual Society for Pediatric Dermatology Meeting: Full Conference Recap

Explore key insights and highlights from SPD 2025, focusing on pediatric dermatology advancements, innovative treatments, and expert reflections from the conference.

Novel PDE4 Inhibitor ME3183 Shows Efficacy for Plaque Psoriasis in Phase 2 Trial

Discover the promising results of ME3183, a novel oral treatment for plaque psoriasis, showing significant efficacy and safety in a recent study.

CHE Severely Impacts Work and Daily Functioning

Explore the complexities of chronic hand eczema, its impact on quality of life, and emerging treatment options in this insightful review.

Jonathan Zalevsky, PhD, on Rezpegaldesleukin’s Biologic Approach to Alopecia Areata

Nektar Therapeutics explores rezpegaldesleukin's potential as a groundbreaking treatment for alopecia areata, aiming for FDA approval and improved patient outcomes.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Videos
© 2025 MJH Life Sciences

All rights reserved.